A
Andreas L. Birkenfeld
Researcher at King's College London
Publications - 203
Citations - 8539
Andreas L. Birkenfeld is an academic researcher from King's College London. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 36, co-authored 113 publications receiving 6362 citations. Previous affiliations of Andreas L. Birkenfeld include Max Delbrück Center for Molecular Medicine & University of Cambridge.
Papers
More filters
Journal ArticleDOI
Intensive lifestyle modifications with or without liraglutide 3 mg vs. sleeve gastrectomy: A three-arm non-randomised, controlled, pilot study
Esmeralda Capristo,Simona Panunzi,A. De Gaetano,Marco Raffaelli,Caterina Guidone,Antonio Iaconelli,Luca L'Abbate,Andreas L. Birkenfeld,Rocco Domenico Alfonso Bellantone,S. R. Bornstein,G. Mingrone,G. Mingrone +11 more
TL;DR: At least in the short-term, liraglutide 3.0mg once daily associated with drastic calorie-intake restriction and intensive physical activity promoted a 24% weight loss, which was almost two times greater than ILM alone and only about 25% less than with SG, while preserving lean body mass.
Journal ArticleDOI
Adipocyte-specific blockade of gamma-secretase, but not inhibition of Notch activity, reduces adipose insulin sensitivity.
David P. Sparling,Junjie Yu,Kyeong Jin Kim,Changyu Zhu,Sebastian Brachs,Andreas L. Birkenfeld,Utpal B. Pajvani +6 more
TL;DR: Notch signaling is dispensable for normal adipocyte function, but adipocyte-specific γ-secretase blockade reduces adipose insulin sensitivity, suggesting that specific Notch inhibitors would be preferable to GSIs for application in T2D.
Journal ArticleDOI
The role of hepatokines in NAFLD.
TL;DR: In this article , the dysregulation of hepatokines in people with non-alcoholic fatty liver disease (NAFLD) was discussed. And the determination of major hepatokine and adipokines can be used for pathomechanism-based clustering of insulin resistance in NAFLD and visceral obesity to better implement precision medicine in clinical practice.
Journal ArticleDOI
Obesity and Impaired Metabolic Health Increase Risk of COVID-19-Related Mortality in Young and Middle-Aged Adults to the Level Observed in Older People: The LEOSS Registry
Norbert Stefan,Katrin Sippel,Martin Heni,Andreas Fritsche,Robert Wagner,Carolin Jakob,Hubert Preissl,Alexander von Werder,Yascha Khodamoradi,Stefan Borgmann,Maria Rüthrich,Frank Hanses,Martina Haselberger,C. Piepel,Martin Hower,Jürgen vom Dahl,Kai Wille,Christoph Römmele,Janne Vehreschild,Melanie Stecher,Michele Solimena,Michael Roden,Annette Schürmann,Baptist Gallwitz,Martin Hrabé de Angelis,David S. Ludwig,Matthias B. Schulze,Bjoern Jensen,Andreas L. Birkenfeld +28 more
TL;DR: The modifiable risk factors obesity, diabetes and hypertension increase the risk of COVID-19-related mortality in young and middle-aged patients to the level of risk observed in advanced age, specifically in the absence of obesity and impaired metabolic health.
Journal ArticleDOI
Obesity Does Not Modulate the Glycometabolic Benefit of Insoluble Cereal Fibre in Subjects with Prediabetes-A Stratified Post Hoc Analysis of the Optimal Fibre Trial (OptiFiT).
Stefan Kabisch,Nina Marie Tosca Meyer,Caroline Honsek,Christiana Gerbracht,Ulrike Dambeck,Margrit Kemper,Martin A. Osterhoff,Andreas L. Birkenfeld,Ayman M. Arafat,Martin O. Weickert,Martin O. Weickert,Martin O. Weickert,Andreas Pfeiffer +12 more
TL;DR: The state of obesity does not relevantly modulate the beneficial effect of cereal fibre on major glycometabolic parameters by fibre supplementation, but leukocyte levels may be affected.